Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC,

The combination of lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic renal cell carcinoma, including in subsets of patients who had received or were naïve to checkpoint inhibitors.

Related Keywords

Chan Lee , Database Consortium , International Metastatic , Memorial Sloan Kettering Cancer Center , Kidney Cancer Research Summit , Cancer Research , Lenvatinib , Pembrolizumab , Nrcc , Renal Cell Carcinoma ,